Table 2.
Summary of selected features of effectiveness evaluations of WHO's emergency use listed vaccines irrespective of country economic status.
| Vaccine | Study Design |
Effectiveness by Host Factors |
Effectiveness by Regimen |
Effectiveness by Outcome |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort | Test negative case control | Screening method | Health Care Workers | Elderly | Comorbidities | Ethnic groups | One or more doses | Single Dose Vs Two doses | Asymptomatic | Severe disease | Variant of Concern* |
||||
| Alpha | Beta | Delta | Gamma | ||||||||||||
|
BNT162b2 (BioNTech/Pfizer), mRNA Vaccine (n = 48) |
33 | 14 | 1 | 21 | 29 | 9 | 5 | 21 | 27 | 13 | 23 | 13 | 3 | 4 | 3 |
|
mRNA-1273 (Moderna); mRNA Vaccine (n = 15) |
6 | 9 | – | 6 | 7 | 5 | 3 | 3 | 12 | 5 | 9 | 4 | 3 | 1 | 2 |
| ChAdOx1 nCoV-19/AZD1222 (AstraZeneca/ University of Oxford); Viral Vector Vaccine (n = 15) | 8 | 6 | 1 | 1 | 9 | 1 | 2 | 8 | 7 | 2 | 10 | 8 | 1 | 4 | 1 |
| CoronaVac (Sinovac Biotech), Inactivated Vaccine (n = 4) |
2 | 2 | – | 2 | 2 | 2 | 1 | 1 | 3 | – | 1 | 1 | 1 | – | 3 |
| Covishield (Serum Institute of India), Viral Vector Vaccine (n = 3) |
2 | 1 | – | 3 | 1 | 1 | – | – | 3 | – | 2 | – | – | – | – |
⁎
Studies estimating effectiveness against more than one variant were counted individually.